Since last summer, several drugmakers have recalled their generic valsartan medications after the FDA discovered that some lots of the drug contained a probable human carcinogen.
After the initial recall, the FDA found that other types of generic blood pressure medications containing losartan or irbesartan were tainted with the probable cancer-causing impurities as well.
“We know that the ongoing recalls to prevent certain lots of valsartan that contain unacceptable limits of impurities from reaching patients has resulted in a shortage of these important medicines,” said FDA Commissioner Scott Gottlieb, MD.
The FDA prioritized review of the new generic, Diovan, to address the shortage.
Read the full news release here.
More articles on pharmacy:
Bristol-Myers urges shareholders to support Celgene takeover
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Martin Shkreli reportedly running his pharma company from prison
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.